Press Releases

Press Releases

SOLICITATION IS NOT AUTHORISED OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE AN OFFER OR SOLICITATION. THE SECURITIES OF IGEA PHARMA N.V. HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT OF 1933, AS AMENDED. THERE WILL BE NO PUBLIC OFFER OF THESE SECURITIES IN THE UNITED STATES.

Press release

Listing of IGEA Pharma N.V.

Amsterdam, December 17, 2018. IGEA Pharma N.V. announced today that it will list all of its ordinary shares on SIX Swiss Exchange as of December 20, 2018 under the ticker symbol ‘IGPH’.

The listed ordinary shares have a par value of EUR 0.01 each (the “Shares”). The indicative reference price for the Shares has been set at CHF 3.75 (EUR 3.33, based on today’s CHF/EUR exchange rate). A public offering of the company’s Shares has not taken place prior to the listing.

Key Data

Trading venue …………………………………… SIX Swiss Exchange
Regulatory standard ……………………………… International Reporting Standard
Ticker Symbol for the Shares ……………………… IGPH
International Security Identification Number (ISIN) …. NL0012768675
(Indicative) Reference price for the Shares ………… CHF 3.75
This press release and further information on IGEA Pharma N.V. can be found at www.igeapharma.nl

Contact

IGEA Pharma N.V.
Diego Mortillaro, CEO
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
+31 23 568 94 94

About IGEA Pharma N.V.

IGEA Pharma N.V. (IGEA) is the holding of a group of companies operating in the prevention of degenerative diseases. IGEA offers medical testing devices and dietary supplements. IGEA has developed an innovative test to measure Free Copper II in the blood stream. Free Copper II is an established marker of Wilson disease now considered one of the major modifiable risk factors of Alzheimer’s disease (“AD”) and Diabetes Type II (“DBT2”). Based on more than twenty years of validated scientific research, it is proven that free copper can predict the progression of cognitive decline and is a risk factor for AD and DBT2. Reducing and controlling Free Copper II can reduce up to three and nine times the risk of AD and DBT2.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION
WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE
INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.

This document does neither constitute an offer to buy or to subscribe for securities of IGEA Pharma N.V. nor a
prospectus within the meaning of applicable Swiss law (i.e. Art. 652a or Art. 1156 of the Swiss Code of
Obligations or Art. 27 et seq. of the SIX Swiss Exchange Listing Rules). Investors should make their decision to
buy or exercise subscription rights or to buy or to subscribe to shares of IGEA Pharma N.V. solely based on the
official prospectus (the “Prospectus”) published by IGEA Pharma N.V. on December 14, 2018. Investors are
furthermore advised to consult their bank or financial adviser before making any investment decision.

This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”,
assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forwardlooking
statements are subject to known and unknown risks, uncertainties and other factors which may result
in a substantial divergence between the actual results, financial situation, development or performance of the
company and those explicitly or implicitly presumed in these statements. Against the background of these
uncertainties, readers should not rely on forward-looking statements. IGEA Pharma N.V. assumes no
responsibility to update forward-looking statements or to adapt them to future events or developments.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any
jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration
or qualification under the securities laws of any jurisdiction.

This announcement is not for distribution, directly or indirectly, in or into the United States (including its
territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan,
Australia or any jurisdiction into which the same would be unlawful. This announcement does not constitute or
form a part of any offer or solicitation to purchase, subscribe for or otherwise acquire securities in the United
States, Canada, Japan, Australia or any jurisdiction in which such an offer or solicitation is unlawful. IGEA
Pharma N.V.’s shares have not been and will not be registered under the US Securities Act of 1933, as amended
(the “Securities Act”) or under any securities laws of any state or other jurisdiction of the United States and
may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly,
within the United States except pursuant to an applicable exemption from, or in a transaction not subject to,
the registration requirements of the Securities Act and in compliance with any applicable securities laws of any
state or other jurisdiction of the United States. Subject to certain exceptions, the IGEA Pharma N.V. shares are
being offered and sold only outside the United States in accordance with Regulation S under the Securities Act.
There will be no public offer of these securities in the United States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom.
No prospectus offering securities to the public will be published in the United Kingdom. This document is only
being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment
professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be
communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as
“relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe,
purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who
is not a relevant person should not act or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to this communication in any
EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that
Member State within the meaning of the Prospectus Directive.

Igea Pharma Company Presentation